Alzinova has previously announced that Kristina Torfgård wishes to leave her position as CEO. Carol Routledge, who has been a board member of the company since 2018, will therefore take up the position as acting CEO from 1 August 2024 until a permanent successor has been appointed.

Carol Routledge, who holds a BSc and PhD in Neuropharmacology, is a research and development, and pharmaceutical expert with more than 30 years' experience in UK and US-based pharmaceutical and biotechnology companies, focussing on drug acquisition and NCE biology profiling. She has played a key role within GSK Biopharmaceuticals, including leadership in pharmaceutical research and development across multiple therapeutic areas, particularly in the areas of immunoinflammatory diseases and neuroscience with an emphasis on translational medicine. Carol, who has more than 90 papers published in scientific journals, has previously held roles including Director of Research and Managing Director of EDoN, a global early detection initiative for Alzheimer's disease at Alzheimer's Research UK. Carol Routledge has worked as Chief Medical and Scientific Officer at Small Pharma and is currently an independent biomedical consultant. With her extensive experience and background in the pharmaceutical industry, Carol is ideally placed to lead Alzinova during this period of transition. In parallel with Carol Routledge's appointment, the Board will continue the process of searching for a permanent successor.

"First and foremost, I would like to once again extend my and the Board's warm thanks to Kristina for her valuable work during the more than four years she has been at Alzinova. As we now look ahead, we are extremely pleased that Carol is stepping in as interim CEO until we have a permanent solution fully in place. Carol, who has been part of the board for many years, is, through her long experience and expertise an absolutely perfect match given the very exciting situation we are in", comments Julian Aleksov, Alzinova's Chairman of the Board.

About Alzinova
Alzinova AB is a Swedish clinical-stage biopharma company specializing in the treatment of Alzheimer’s disease targeting toxic amyloid beta oligomers. The lead candidate, ALZ-101, is being developed as a therapeutic vaccine for the treatment of Alzheimer's. Alzinova’s proprietary AβCC peptide™ technology enables the development of disease-modifying treatments that target the toxic amyloid beta oligomers involved in the onset and progression of the disease with high precision. Alzheimer’s is one of the most common and devastating neurological diseases globally, with of the order of 40 million people afflicted today. In addition, the antibody ALZ-201 is in preclinical development, and the ambition is to expand the pipeline further. The company’s Certified Adviser on Nasdaq First North Growth Market is Mangold Fondkommission AB. For more information about Alzinova, please visit: www.alzinova.com